Browse drugs

…particularly relevant for GLP-1 receptor agonists. For example, semaglutide has demonstrated dose-dependent effects on glycemic control and…

…ltiple risk factors for cardiovascular disease, irrespective of metformin use.14–19Despite the demonstrated benefits of SGLT2i and GLP-1R…

… discussing urinary symptoms with patients prior to prescribing SGLT2is. Further research is critically needed to address these issues …

…therapy with SGLT2i and GLP-1 RA relative to those who received SGLT2i monotherapy was significantly lower in patients with HF and T2D…

…ple with T2DM and established CVD to receive either the SGLT2i, empagliflozin, or placebo.5 To be eligible for this study, people had to meet…

…ilar course in their T2DM trajectory compared with those not on metformin). For individuals with multiple COVID-19 tests, we excluded all…

… (SGLT2i: adjusted median OR (aMOR) 1.29 (95% CI 1.23 to 1.36); GLP-1 RA: aMOR 1.48 (95% CI 1.37 to 1.62)). Treating all patients would …

…ssociation. One potential explanation is the high prevalence of statin use among patients, which may have attenuated the variability i…

…ristics and outcomes of patients with T2D and CKD who initiated SGLT2i or GLP-1 RA in China. The results are important for understandi…

…their proven efficacy, there remains a gap in the initiation of Sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus patients with evidence of coronary …

…nd 0.49 (95% CI 0.41 to 0.58) to 0.93 (95% CI 0.72 to 1.20) for SGLT2i. Prescriptions for both ARNi and SGLT2i showed a social gradien…

…n, decreased pancreatic β-cell function and the combined use of metformin may also contribute to the risk of DKA in patients treated with…